These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 36918276)

  • 1. Metformin Monotherapy Alters the Human Plasma Lipidome Independent of Clinical Markers of Glycemic Control and Cardiovascular Disease Risk in a Type 2 Diabetes Clinical Cohort.
    Wancewicz B; Zhu Y; Fenske RJ; Weeks AM; Wenger K; Pabich S; Daniels M; Punt M; Nall R; Peter DC; Brasier A; Cox ED; Davis DB; Ge Y; Kimple ME
    J Pharmacol Exp Ther; 2023 Aug; 386(2):169-180. PubMed ID: 36918276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
    Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
    Cardiovasc Diabetol; 2021 Jul; 20(1):160. PubMed ID: 34332584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men.
    Rosell-Díaz M; Petit-Gay A; Molas-Prat C; Gallardo-Nuell L; Ramió-Torrentà L; Garre-Olmo J; Pérez-Brocal V; Moya A; Jové M; Pamplona R; Puig J; Ramos R; Bäckhed F; Mayneris-Perxachs J; Fernández-Real JM
    Metabolism; 2024 Aug; 157():155941. PubMed ID: 38871078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.
    Abbasi F; Chu JW; McLaughlin T; Lamendola C; Leary ET; Reaven GM
    Metabolism; 2004 Feb; 53(2):159-64. PubMed ID: 14767866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
    Rodríguez A; Reviriego J; Karamanos V; del Cañizo FJ; Vlachogiannis N; Drossinos V;
    Cardiovasc Diabetol; 2011 Feb; 10():18. PubMed ID: 21314919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
    Cusi K; Consoli A; DeFronzo RA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4059-67. PubMed ID: 8923861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
    Jendle J; Hyötyläinen T; Orešič M; Nyström T
    Cardiovasc Diabetol; 2021 Dec; 20(1):237. PubMed ID: 34920733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
    Dailey GE; Mohideen P; Fiedorek FT
    Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bidirectional modulation of TCA cycle metabolites and anaplerosis by metformin and its combination with SGLT2i.
    Harada M; Adam J; Covic M; Ge J; Brandmaier S; Muschet C; Huang J; Han S; Rommel M; Rotter M; Heier M; Mohney RP; Krumsiek J; Kastenmüller G; Rathmann W; Zou Z; Zukunft S; Scheerer MF; Neschen S; Adamski J; Gieger C; Peters A; Ankerst DP; Meitinger T; Alderete TL; de Angelis MH; Suhre K; Wang-Sattler R
    Cardiovasc Diabetol; 2024 Jun; 23(1):199. PubMed ID: 38867314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy for type 2 diabetes: dapagliflozin plus metformin.
    Tan X; Hu J
    Expert Opin Pharmacother; 2016; 17(1):117-26. PubMed ID: 26567559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.
    Seufert J; Lübben G; Dietrich K; Bates PC
    Clin Ther; 2004 Jun; 26(6):805-18. PubMed ID: 15262452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin: New Preparations and Nonglycemic Benefits.
    Fujita Y; Inagaki N
    Curr Diab Rep; 2017 Jan; 17(1):5. PubMed ID: 28116648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
    Wang J; Ciaraldi TP; Samad F
    J Obes; 2015; 2015():291209. PubMed ID: 25861467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin.
    Zhang C; Ma S; Wu J; Luo L; Qiao S; Li R; Xu W; Wang N; Zhao B; Wang X; Zhang Y; Wang X
    Pharmacol Res; 2020 Sep; 159():104985. PubMed ID: 32504839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes.
    Xu T; Brandmaier S; Messias AC; Herder C; Draisma HH; Demirkan A; Yu Z; Ried JS; Haller T; Heier M; Campillos M; Fobo G; Stark R; Holzapfel C; Adam J; Chi S; Rotter M; Panni T; Quante AS; He Y; Prehn C; Roemisch-Margl W; Kastenmüller G; Willemsen G; Pool R; Kasa K; van Dijk KW; Hankemeier T; Meisinger C; Thorand B; Ruepp A; Hrabé de Angelis M; Li Y; Wichmann HE; Stratmann B; Strauch K; Metspalu A; Gieger C; Suhre K; Adamski J; Illig T; Rathmann W; Roden M; Peters A; van Duijn CM; Boomsma DI; Meitinger T; Wang-Sattler R
    Diabetes Care; 2015 Oct; 38(10):1858-67. PubMed ID: 26251408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of efficacy and tolerability of gliclazide and metformin combination: a multicentric study in patients with type 2 diabetes mellitus uncontrolled on monotherapy with sulfonylurea or metformin.
    Pareek A; Chandurkar N; Zawar S; Agrawal N
    Am J Ther; 2010; 17(6):559-65. PubMed ID: 20093927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacement of dietary saturated with unsaturated fatty acids is associated with beneficial effects on lipidome metabolites: a secondary analysis of a randomized trial.
    Sellem L; Eichelmann F; Jackson KG; Wittenbecher C; Schulze MB; Lovegrove JA
    Am J Clin Nutr; 2023 Jun; 117(6):1248-1261. PubMed ID: 37062359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is insulin the preferred treatment for HbA1c >9%?
    Bloomgarden Z
    J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.